Targeting IL-5 with biologics such as mepolizumab has shown efficacy in reducing eosinophilic inflammation [51] as well as reducing the sub-basement membrane thickness and the airway smooth muscle area [52] However, our findings suggest that anti-IL-5/IL-5Rα therapies may also mitigate fibroblast-driven fibrosis, addressing a critical unmet need in severe asthma management. The gene discussed is IL5; the disease is inflammatory response.